AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04662983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-training
Description: A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
Study NCT00115336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketorolac
Description: Intravenous ketorolac
Study NCT00115336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen, taken orally
Study NCT01743976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil 5 mg once daily for 6 weeks
Study NCT01743976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo or sugar pill will be taken once daily for 6 weeks
Study NCT02351336 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: 1. - Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~2. - corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~3. - CL measurement using 2D ultrasound ( in cm)
Study NCT05037253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
Study NCT01232400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~1. Heart rate less than 70 bpm.~2. Systolic blood pressure less than 120 mmHg~3. Maximum dose of esmolol of 200 mcg/kg/minute is reached.
Study NCT01966978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Study NCT01966978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Study NCT01966978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
Study NCT01966978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG \<180
Study NCT03540290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modification of the implant supported prostheses in order to facilitate oral hygiene
Description: Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
Study NCT03540290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modification of the implant supported prostheses in order to facilitate oral hygiene
Description: Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
Study NCT04116606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active JNJ-54175446
Description: JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
Study NCT04116606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing the same excipients
Study NCT03208608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RBANS-H
Description: The RBANS-H is a diagnostic cognitive test battery
Study NCT01553435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: The study medicines shall be administered via tube.
Study NCT01553435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medicines shall be administered via tube.
Study NCT03749109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 1080 µg
Description: Vaginal ring containing Quinagolide 1080 µg for daily releases
Study NCT03749109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02215785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiwifruit
Description: Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
Study NCT02081937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR vector-transduced T cells
Study NCT03559829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAPAEL Smart Glove
Description: The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
Study NCT01536197 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: Roux-en-Y gastric bypass
Study NCT01536197 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric banding
Description: Laparoscopic adjustable gastric banding
Study NCT01536197 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy surgery
Study NCT04631588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Intradermal (ID) injection
Study NCT04631588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal (ID) injection
Study NCT03714542 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre- and postoperative MRI
Study NCT01454388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breakfast
Study NCT04477356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SU
Description: Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
Study NCT04477356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DG
Description: Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
Study NCT04567810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 IgY
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
Study NCT04567810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
Study NCT04286763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biliary RMI and CT scan.
Description: For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients.
Study NCT02914171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow-derived Mononuclear Cells
Study NCT02914171 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insertable cardiac monitor
Description: Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
Study NCT02914171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor
Description: Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
Study NCT02188394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetic blockades with bupivacaine
Study NCT02188394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline injection
Study NCT04211311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid high-intensity training
Description: FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
Study NCT02294097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surveillance protocol kidney allograft biopsy
Description: Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
Study NCT02928211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire II
Description: A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
Study NCT02928211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aftobetin-HCl
Description: The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
Study NCT02928211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
Study NCT01692093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KM110329
Description: KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
Study NCT01692093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02720211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gray tinted spectacle lenses
Description: A neutral gray optical tint designed to block all wavelengths in the visible spectrum
Study NCT02720211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thin-Film spectacle lenses
Description: A thin film optical notch filter designed to block 480-nm light in the visible spectrum
Study NCT00359047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Documentation
Description: Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
Study NCT00359047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
Study NCT01536171 — intervention group
Intervention type: OTHER
Intervention: running with normal running shoes and barefoot
Description: shod condition: normal running shoes barefoot condition: running with no shoewear
Study NCT02849405 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MHRC: Metabolic Hyperspectral Retinal Camera
Description: Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
Study NCT01748305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity exercise
Description: Moderate-to-vigorous intensity exercise three times per day for three weeks
Study NCT03928392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCUBA with Occupational Therapy (OT)
Description: Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.
Study NCT03928392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Contained Underwater Breathing Apparatus (SCUBA) without OT
Description: Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
Study NCT00288223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telithromycin
Description: one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
Study NCT05168098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: board game comparison
Description: The group used 24 board games popular among the elderly population in Taiwan, including Noah's Ark, Splash Attack, Pengoloo, Speedy, and Zingo. Because some games were too complicated for the participants to play, some game rules were modified into more simple and directive thinking.
Study NCT00892515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Study NCT00892515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study NCT05168098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactory stimulation intervention
Description: The group used 15 flavors of essential oil (i.e., lavender, rosemary, sweet orange, lemongrass, mint, and hinoki) and essence (i.e., lemon, coffee, peach, magnolia, chocolate, jasmine, strawberry, pomelo, and passion fruit), purposefully selecting two to three flavors for each session. Because some flavors are familiar to the participants and some are not, the familiar flavors were initially used to trigger memory. The unfamiliar flavors (i.e., lavender, rosemary, sweet orange, and lemon) were used in later sessions because those were recognized as having potential effects on cognitive function
Study NCT04191408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP increase
Description: PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
Study NCT01621789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dye of lutein, zeaxanthin, trypan blue
Description: dye composed of lutein, zeaxanthin, trypan blue
Study NCT02900898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic exercise and Mediterranean diet
Description: DE, MD
Study NCT02900898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Description: DE
Study NCT02900898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: MD
Study NCT02900898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control
Study NCT04271046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-C-VTF
Description: 1. One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~2. Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~3. secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months.
Study NCT04271046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm.
Study NCT04451837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Ozempic s.c. once weekly for 6 months
Study NCT04451837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Forxiga 10 mg p.o. once daily for 6 months
Study NCT02421536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrogent Smartphone Application
Study NCT02780895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Stem Cells
Description: MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery.
Study NCT01486381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin)
Study NCT00885326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
Study NCT00885326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
Study NCT00885326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: zoledronic acid
Description: Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
Study NCT02854618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Study NCT00801411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00801411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV